NCT03366051 (ALICE) is a NA clinical trial of Sentinel Node Mapping in Endometrial Cancer, sponsored by AC Camargo Cancer Center.

Who is sponsoring NCT03366051?

NCT03366051 is sponsored by AC Camargo Cancer Center.

What drugs are being tested in NCT03366051?

Interventions in NCT03366051: Sentinel Node Mapping, Lymphadenectomy.

What condition does NCT03366051 study?

NCT03366051 studies Endometrial Cancer, Lymph Node Metastases.

Is NCT03366051 still recruiting?

NCT03366051 is currently recruiting now. Last updated 30 July 2024.

Last reviewed 2024-07-30 · How we verify

NCT03366051: ALICE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sentinel Node Mapping in High Risk Endometrial Cancer

Recruiting now NA Last updated 30 July 2024

What this trial tests

NA trial testing Sentinel Node Mapping in Endometrial Cancer in 178 participants. Currently enrolling.

Timeline

22 December 2017

Primary endpoint
20 December 2024

20 December 2024

Quick facts

Lead sponsor	AC Camargo Cancer Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	178
Start date	22 December 2017
Primary completion	20 December 2024
Estimated completion	20 December 2024
Sites	5 locations across Brazil

Drugs / interventions tested

Sentinel Node Mapping
Lymphadenectomy

Conditions studied

Endometrial Cancer — all drugs for Endometrial Cancer →
Lymph Node Metastases — all drugs for Lymph Node Metastases →

Sponsor

AC Camargo Cancer Center — full company profile →

Who can join

Adults 18 to 75, female only, with Endometrial Cancer or Lymph Node Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the role of systematic lymphadenectomy after sentinel node (SLN) mapping in high risk endometrial cancer (high grade histologies or deep myometrial invasion). The participants will be randomized in a non-inferiority controlled trial in 2 groups: SLN mapping or SLN mapping followed by systematic lymphadenectomy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Sentinel lymph node mapping versus sentinel lymph node mapping with systematic lymphadenectomy in endometrial cancer: an open-label, non-inferiority, randomized trial (ALICE trial).
Baiocchi G, Andrade CEMC, Ribeiro R, Moretti-Marques R, et al · · 2022 · cited 34× · PMID 35236752 · DOI 10.1136/ijgc-2022-003378
Sentinel Lymph Node Assessment in Endometrial Cancer: A Review.
Clark C, Loizzi V, Cormio G, Lopez S. · · 2024 · cited 3× · PMID 39335173 · DOI 10.3390/cancers16183202
Comparison of tracer application methods for sentinel lymph node detection in open surgery patients with endometrial cancer: a retrospective cohort study.
Sehnal B, Waldauf P, Matej R, Hruda M, et al · · 2025 · PMID 40200256 · DOI 10.1186/s12885-025-14037-8

Verify or expand the search:

Other recruiting trials for Endometrial Cancer

Currently open trials in the same condition.

NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting

Other AC Camargo Cancer Center trials

Trials by the same sponsor.

NCT07285356 — Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy · NA · recruiting
NCT07268846 — Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery · NA · recruiting
NCT06793137 — Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT06472388 — Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors · Phase 2 · recruiting
NCT06207487 — Evaluation of Herpes Zoster Characteristics and Costs in Cancer Population. · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03366051 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AC Camargo Cancer Center
Last refreshed: 30 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03366051.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing